ArticleJournal of the American Board of Family Medicine : JABFM
Patients' survival expectations before localized prostate cancer treatment by treatment status.
Article in Journal of the American Board of Family Medicine : JABFM. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Pooled it
- Pooled it
- Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk.World journal of urology · 2017Article
- Patients' Survival Expectations With and Without Their Chosen Treatment for Prostate Cancer.Annals of family medicine · 2016Article
- Factors influencing the attitudes of Chinese cancer patients and their families toward the disclosure of a cancer diagnosis.Journal of cancer education : the official journal of the American Association for Cancer Education · 2015Article
- Quality of physician-patient relationships is associated with the influence of physician treatment recommendations among patients with prostate cancer who chose active surveillance.Urologic oncology · 2014Article
- Suboptimal health literacy in patients with lung cancer or head and neck cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2013Article
- Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance.BJU international · 2013Article
- Self-rated health as a tool for estimating health-adjusted life expectancy among patients newly diagnosed with localized prostate cancer: a preliminary study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2011Article
- Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention?BJU international · 2011Article
- Impact of comorbidity on survival among men with localized prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Article
- Development of a scale to assess patient misperceptions about treatment choices for localized prostate cancer.BJU international · 2010Article
- ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS.Journal of applied econometrics (Chichester, England)Article
Corrections and comments
- Commented on by
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCancer-specific mortality is projected to be only 1% in 15 years in approximately 75% of patients with screen-detected localized prostate cancer (LPC). Nearly 94% of patients choose treatment even though treatment damages health-related quality of life. No data are available regarding what survival benefit patients expected from treatment.
objectivesA self-administered mailed survey was sent to 184 men with newly diagnosed LPC to query patients about expected survival with treatment versus observation.
resultsMore than 90% of patients had at least a high school education and a ninth-grade health literacy. In addition, 68% patients had income of > or =$50,000. Mean cancer grade was 6.6. Twenty-three patients chose observation and 161 patients chose surgery or radiotherapy. Mean comorbidity adjusted life expectancy (CALE) without the cancer was 22.9 years. Without cancer treatment, 15.2% of patients expected to live <5 years, 48.8% 5 to 10 years, 33.5% 11 to 19 years, and 2.4% > or =20 years. With treatment, survival expectations were <5 years in 0.6%, 5 to 10 years in 6.5%, 11 to 19 years in 30.0%, and > or =20 years in 62.9% of patients. Age, prostate-specific antigen level, CALE, anxiety, depression, and social support were factors that predicted differences between CALE and patient survival expectations with and without treatment.
conclusionLPC patients grossly underestimated their life expectancy without treatment and grossly overestimated the survival benefit of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.